tbuckley/cabot-search huggingface dataset:
Treatment of Corticosteroid-Refractory Graft-Versus-Host Disease with Ruxolitinib in 95 Patients
Authors: Robert Zeiser, Andreas Burchert, Claudia Lengerke, Mareike Verbeek, Kristina Maas-Bauer, Stephan Metzelder, Silvia Spoerl, Markus Ditschkowski, Matyas Ecsedi, Katja Sockel, Francis Ayuk, Salem Ajib, Flore Sicre de Fontbrune, Il-Kang Na, Livius Penter, Udo Holtick, Dominik Wolf, Esther Schuler, Everett Meyer, Petya Apostolova, Hartmut Bertz, Reinhard Marks, Michael Luebbert, Ralph M. Waesch, Christof Scheid, Friedrich Stölzel, Rainer Ordemann, Gesine Bug, Guido Kobbe, Robert Negrin, Mats L Brune, Alexandros Spyridonidis, Annette Schmitt-Graeff, Walter van der Velden, Gerwin Huls, Stephan Mielke, Goetz Ulrich Grigoleit, Jurgen Kuball, Ryan P Flynn, Gabriele Ihorst, Jing Du, Bruce R. Blazar, Renate Arnold, Nicolaus Kröger, Joerg Halter, Gerard Socie, Dietrich Beelen, Christian Peschel, Andreas Neubauer, Juergen Finke, Justus Duyster, Nikolas von Bubnoff
Journal: Blood (2015)
Prognostic Significance of Mutations In Isocitrate Dehydrogenase (IDH) Enzyme Isoforms 1 and 2 and Single Nucleotide Polymorphisms (SNP) In IDH1, In Patients with Acute Myeloid Leukemia Treated with High Dose Cytarabine and Idarubicin Induction
Authors: Farhad Ravandi, Keyur P. Patel, Rajyalakshmi Luthra, Stefan Faderl, Marina Konopleva, Tapan Kadia, Mark Brandt, Sherry Pierce, Steven M. Kornblau, Guillermo Garcia-Manero, Jorge E. Cortes, Hagop Kantarjian
Journal: Blood (2010)
Outcome of Older AML Patients with Adverse Cytogenetics, Including Single or Multiple Monosomies, Treated with the DNA Hypomethylating Agent Decitabine
Authors: Michael Lübbert, Claudia Schmoor, Anne Hagemeijer, Björn Hackanson, Rainer Claus, Björn Rüter, Mathias Schmid, Ulrich Germing, Andrea Kuendgen, Volker Rethwisch, Arnold Ganser, Uwe Platzbecker, Oliver Galm, Wolfram Brugger, Gerhard Heil, Pierre W. Wijermans, Konstanze Döhner, Hartmut Döhner
Journal: Blood (2011)
Heart of the Matter? Early Ventricular Dysfunction in Congenital Diaphragmatic Hernia
Authors: David G. Tingay, John P. Kinsella
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

In their conclusions, the authors state that early initiation of noninvasive ventilation (NIV) may have impacted patients' quality of life and survival, particularly in the rapid progressor group.This is debatable, as studies in other neuromuscular disorders (such as muscular dystrophy) have shown that "preventive" initiation of NIV was not successful in slowing or preventing progression of disease (10).In fact, patients with close to normal VC often resist the use of NIV until their VCs have decreased to low levels (,30% predicted or 1 L) or there is associated bulbar dysfunction.The authors are to be commended for performing a thoughtful and sophisticated analysis of a feature of ALS that has been described in general terms for the last half century, namely, the variability in functional decline.Clearly, the next step would be to conduct genetic analyses in a large population of patients in an attempt to identify plasma biomarkers that predict the onset and timing of respiratory insufficiency long before patients are confronted with decisions regarding goals of care.Better yet, identification of such genetic biomarkers could lead to targeted, patient-centered therapies that would halt and perhaps even reverse the (currently) inexorable decline in respiratory function.
Engraftment of Human MDS Samples in Xenotransplanted Mice Depends on Human Cytokines but Not Mesenchymal Stem Cells (MSC)
Authors: Maria Krevvata, Cedric Dos Santos, Xiaochuan Shan, Selene Nunez-Cruz, Anthony Secreto, Michael Milone, Gwenn Danet-Desnoyers, Martin Carroll
Journal: Blood (2016)
Effect of Multi-professional Cooperation on Location for End-of-life care in Patients with Hematologic Malignancies
Authors: Rika Kihara, Yasuko Torii, Yumi Ishiguri, Yasuyuki Asai, Norihiro Ueda, Tsuyuki Takatsu, Tsukasa Honjo, Haruka Sato, Akiko Kumon, Yasuhiro Osada, Tomohiro Fukuoka, Masae Toda, Keiko Furui, Sakae Sako, Takuya Odagiri, Hiroaki Watanabe, Koichi Watamoto
Journal: Annals of Oncology (2019)
Infusion of Recombinant Full-Length ADAMTS13 and Carboxyl-Terminal Truncated Variant Alters Composition of Ferric Chloride-Induced Arterial Thrombi in Adamts13−/− mice
Authors: Christopher G. Skipwith, Juan (Jenny) Xiao, John W. Weisel, X. Long Zheng
Journal: Blood (2011)
Comparison of Dosimetry and Gamma Camera Methods for Evaluation of Biodistribution Prior to Administration of the Therapeutic Dose of Tositumomab and Iodine I 131 Tositumomab (Bexxar Therapeutic Regimen)
Authors: Thierry J. Horner, Jeffry A. Siegel, Roxanne C. Jewell, Gary J. Lunger, Nancy L. Young, Brian R. Wynne, Vanessa C. Williams, Thomas S. Lin, Mark S. Kaminski, Richard L. Wahl, Christina Vleisides
Journal: Blood (2010)
Causes of Death in the Highly Active Antiretroviral (HAART) Era: A Retrospective Comparison between a Hybrid HIV and Hematology/Oncology Practice and the Adult &amp; Adolescent Spectrum of HIV-Related Diseases (ASD) Project.
Authors: Matthew C. Uhlenkott, Erin Kahle, Susan Buskin, Elizabeth Barash, David M. Aboulafia
Journal: Blood (2006)
Hyper-CVAD Plus Epratuzumab As Salvage Regimen for Younger Relapsed/Refractory CD22+ B Acute Lymphoblastic Leukemia (ALL) Patients: Results of the Phase 2 Prospective Cheprall Study
Authors: Patrice Chevallier, Sylvain Chantepie, Françoise Huguet, Emmanuel Raffoux, Xavier Thomas, Thibaut Leguay, Tony Marchand, Francoise Isnard, Aude Charbonnier, Sebastien Maury, Maria-Pilar Gallego-Hernanz, Nelly Robillard, Thierry Guillaume, Pierre Peterlin, Alice Garnier, Fanny Rialland, Claire Le Houerou, David M Goldenberg, William Wegener, Marie C Bene, Herve Dombret
Journal: Blood (2016)
The Mir-17∼92 Cluster Activates mTORC1 Signaling in MCL by Targeting Multiple Regulators of the LKB1/AMPK/mTOR Pathway
Authors: Chengfeng Bi, Chunsun Jiang, Xiaoxing Jiang, Xin Huang, Mario R Fernandez, Javeed Iqbal, Robert E Lewis, Wing Chung Chan, Timothy McKeithan, Kai Fu
Journal: Blood (2012)
Dose-Escalated, Intratumoral TLR9 Agonist and Low-Dose Radiation Induce Abscopal Effects in Follicular Lymphoma
Authors: Holbrook E Kohrt, Jaqueline Chu, Joshua Brody, Debra K Czerwinski, Cariad Chester, Mohith Sadaram, Ranjana Advani, Youn H. Kim, Richard T. Hoppe, Susan J. Knox, Irene Wapnir, Robert J. Tibshirani, Ron Levy
Journal: Blood (2014)
Abstract 19389: Restoring Cardiac Function After Ischemia-Reperfusion Injury by Targeting Peripheral Blood Mononuclear Cells to Activated Platelets
Authors: Melanie Ziegler, Xiaowei Wang, Bock Lim, Ephraem Leitner, Victoria Chang, Karen Alt, Helen Kiriazis, Christoph E Hagemeyer, Ingo Ahrens, Karlheinz Peter
Journal: Circulation (2017)

Introduction: One of the major hurdles and potential reason of failure of intravenous cell therapy is a low homing efficacy to the heart post MI. Hypothesis: We aimed to develop a highly specific a...
Association Between C-Reactive Protein in the First 1-3 Days Post-Transplant and Allogeneic Immune Reactions in Pediatric Haploidentical Stem Cell Transplantation
Authors: Yao Chen, Kai-Yan Liu, Xiao-Jun Huang, Chen Huan, Feng-Rong Wang, Jing-Zhi Wang, Xiao-Hui Zhang, Yu-Hong Chen, Yu Wang, Wei Han, Yan Chen-Hua, Yuan-Yuan Zhang, Lan-Ping Xu
Journal: Blood (2016)
Transplantation of bone marrow derived macrophages reduces markers of neuropathology in an APP/PS1 mouse model
Authors: Luís Costa-Marques, Katrin Arnold, Marie-Christine Pardon, Christiane Leovsky, Samantha Swarbrick, Claire Fabian, Alexandra Stolzing
Journal: Translational Neurodegeneration (2019)

We investigated early hallmarks of putative therapeutic effects following systemic transplantation of bone marrow derived macrophages (BM-M) in APP/PS1 transgenic mice. BM-M were transplanted into the tail vein and the animals analysed 1 month later. BM-M transplantation promoted the reduction of the amyloid beta [37-42] plaque number and size in the cortex and hippocampus of the treated mice, but no change in the more heavily modified pyroglutamate amyloid beta E3 plaques. The number of phenotypically 'small' microglia increased in the hippocampus. Astrocyte size decreased overall, indicating a reduction of activated astrocytes. Gene expression of interleukin 6 and 10, interferon-gamma, and prostaglandin E receptor 2 was significantly lower in the hippocampus, while interleukin 10 expression was elevated in the cortex of the treated mice. BM-M systemically transplanted, promote a decrease in neuroinflammation and a limited reversion of amyloid pathology. This exploratory study may support the potential of BM-M or microglia-like cell therapy and further illuminates the mechanisms of action associated with such transplants.
Liver Hypoxia and Tissue Injury Are Specific to Sickle Cell Mice in An Experimental Model of Sickle Cell Vaso-Occlusion.
Authors: Lewis L. Hsu, Audrey C Noguchi, Constance Noguchi, Katherine C Wood, James G Taylor, Gregory J. Kato, Mark Gladwin, Bhalchandra Diwan
Journal: Blood (2009)
Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)—a trial by the Asian Myeloma Network
Authors: Cinnie Yentia Soekojo, Kihyun Kim, Shang-Yi Huang, Chor-Sang Chim, Naoki Takezako, Hideki Asaoku, Hideo Kimura, Hiroshi Kosugi, Junichi Sakamoto, Sathish Kumar Gopalakrishnan, Chandramouli Nagarajan, Yuan Wei, Rajesh Moorakonda, Shu Ling Lee, Je Jung Lee, Sung-Soo Yoon, Jin Seok Kim, Chang Ki Min, Jae-Hoon Lee, Brian Durie, Wee Joo Chng
Journal: Blood Cancer Journal (2019)

Abstract Pomalidomide is a third generation immunomodulatory drug which in combination with dexamethasone, has been shown to be active in relapsed/refractory multiple myeloma. However, the data in Asian patients remain limited. We conducted a prospective phase two clinical trial in major cancer centers in Singapore, South Korea, Taiwan, Japan and Hong Kong to assess the efficacy and safety of pomalidomide and dexamethasone combination (PomDex) +/− cyclophosphamide in Asian patients with relapsed/refractory multiple myeloma who failed lenalidomide and bortezomib. Patients were treated with pomalidomide (4 mg daily for 21 days every 4 weeks) and dexamethasone (40 mg weekly). If there is less than a minimal response after three cycles of PomDex, cyclophosphamide 300 mg/m 2 can be added (PomCyDex). A total of 136 patients were enrolled. The median PFS was 9 and 10.8 months for the PomDex and PomCyDex group, respectively. The median OS was 16.3 months. This regimen appears to be active across age groups and prior lines of treatment. This combination was overall well tolerated with grade 3 and 4 adverse events of mainly cytopenias. PomDex is highly active and well-tolerated in Asian patients. The addition of cyclophosphamide can improve the response and outcomes further in patients with suboptimal response to PomDex.
Clinical Impact of KMT2C and SPRY4 Expression Levels in Intensively Treated Younger Adult Acute Myeloid Leukemia Patients
Authors: Sabine Kayser, Maximilian Feszler, Julia Krzykalla, Matthias Schick, Thomas Hielscher, Axel Benner, Michael Kramer, Felicitas Thol, Uwe Platzbecker, Anthony D. Ho, Gerhard Ehninger, Michael Heuser, Christian Thiede, Christoph Röllig, Alwin Krämer
Journal: Blood (2016)
A Phase II Trial of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients with Previously Untreated Indolent Non-Hodgkin’s Lymphoma
Authors: Jonathon B. Cohen, Jeffrey Switchenko, Jean L. Koff, Rajni Sinha, Jonathan L. Kaufman, H. Jean Khoury, Nassoma K Bumpers, Amanda Colbert, Amanda A Hutchison-Rzepka, Loretta J. Nastoupil, Leonard T. Heffner, Amelia Langston, Mary Jo Lechowicz, Sagar Lonial, Christopher R. Flowers
Journal: Blood (2014)
An Open-Label, Phase 1 Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with CD22-Positive B-Cell Non-Hodgkin's Lymphoma: Preliminary Safety and Efficacy Data
Authors: Michinori Ogura, Kiyohiko Hatake, Andrew Davies, Michael Crump, Kensei Tobinai, Mitchell R Smith, Fritz Offner, Shaw-Ling Wang, Taro Ishibashi, Luisa Paccagnella, Erik Vandendries, David A MacDonald
Journal: Blood (2012)
Functions and Regulation of Erythrocyte Equlibrative Nucleoside Transporter 1 (ENT1) in Acute Hypoxia Mediated Tissue Injury
Authors: Anren Song, Cheng Zhao, Yujin Zhang, Jessica Li, Michael R. Blackburn, Almut Grenz, Holger Eltzschig, Rodney E. Kellems, Yang Xia
Journal: Blood (2014)
Sequential phosphorylation of protein band 3 by Syk and Lyn tyrosine kinases in intact human erythrocytes: identification of primary and secondary phosphorylation sites
Authors: Anna Maria Brunati, Luciana Bordin, Giulio Clari, Peter James, Manfredo Quadroni, Elisabetta Baritono, Lorenzo A. Pinna, Arianna Donella-Deana
Journal: Blood (2000)
DYRK2 Inhibits the Self-Renewal of Leukemic Stem Cells in Chronic Myeloid Leukemia By Inducing Degradation of c-Myc Downstream of the Reprogramming Factor KLF4
Authors: Chun Shik Park, Ye Shen, Koramit Suppipat, Andrew Lewis, Julie Tomolonis, Monica Puppi, toni-Ann Mistretta, Leyuan Ma, Michael R Green, Daniel Lacorazza
Journal: Blood (2016)
Cytarabine, Daunorubicin and Etoposide (ADE) Chemotherapy in Acute Myeloid Leukemia (AML) Patients ≥60 Years (CALGB 9720).
Authors: Maria R. Baer, Stephen L. George, Ben L. Sanford, Sandra M. Bothun, Krzysztof Mrozek, Kieran L. O’Loughlin, Jonathan E. Kolitz, Joseph O. Moore, Richard M. Stone, Bayard L. Powell, Michael A. Caligiuri, Clara D. Bloomfield, Richard A. Larson
Journal: Blood (2007)
Rituximab Maintenance after First Line Immunochemotherapy Improves Overall Survival in Patients with Follicular Lymphoma
Authors: Adam Vilmar, Bente Arboe, Par Josefsson, Christian Poulsen, Jacob Haaber Christensen, Judit Jørgensen, Paw Jensen, Jørn Starklint, Per Troellund Pedersen, Michael Pedersen, Peter de Nully Brown
Journal: Blood (2016)
CD4+CD25+Foxp3+ T Regulatory Cells Protect Against Murine Antibody-Mediated Transfusion-Related Acute Lung Injury (TRALI)
Authors: Rick Kapur, Michael Kim, Shanjee Shanmugabhavananthan, Edwin R. Speck, Rukhsana Aslam, Li Guo, Anne Zufferey, John W. Semple
Journal: Blood (2015)
The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance])
Authors: Richard M. Stone, Sumithra Mandrekar, Ben L Sanford, Susan Geyer, Clara D. Bloomfield, Konstanze Dohner, Christian Thiede, Guido Marcucci, Francesco Lo-Coco, Rebecca B. Klisovic, Andrew Wei, Jorge Sierra, Miguel A. Sanz, Joseph M. Brandwein, Theo de Witte, Dietger Niederwieser, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S Tallman, Jurgen Krauter, Richard F. Schlenk, Arnold Ganser, Hubert Serve, Gerhard Ehninger, Sergio Amadori, Richard A. Larson, Hartmut Dohner
Journal: Blood (2015)
A Multicenter, Open Label Phase I/II Study of CEP701 (Lestaurtinib) in Adults with Myelofibrosis; a Report On Phase I: A Study of the Myeloproliferative Disorders Research Consortium (MPD-RC).
Authors: Elizabeth Hexner, Judith D. Goldberg, Josef T. Prchal, Erin P Demakos, Sabina Swierczek, Rona Singer Weinberg, Joseph Tripodi, Vesna Najfeld, Martin Carroll, Roberto Marchioli, Lewis R. Silverman, Ronald Hoffman
Journal: Blood (2009)
Major Improvement of Outcome in Pediatric High-Risk Acute Lymphoblastic Leukemia by Addition of BFM Chemotherapy Element “Phase IB”: A Comparative Data Analysis of Trials ALL-BFM 95 and ALL-BFM 2000
Authors: Anja Möricke, André Schrauder, Martin Zimmermann, Georg Mann, Andishe Attarbaschi, Rolf Koehler, Renate Panzer-Grümayer, Martin Stanulla, Gunnar Cario, Alfred Reiter, Felix Niggli, Claus R Bartram, Martin Schrappe
Journal: Blood (2011)
Early Mortality in Patients with Acute Promyelocytic Leukemia (APL) Treated in Teaching Versus Non-Teaching Hospitals
Authors: Adam Levin, Ariel Kleman, Lisa Rein, Sergey Tarima, Laura C Michaelis, Karen-Sue B. Carlson, Mehdi Hamadani, Timothy S. Fenske, Parameswaran Hari, Ehab Atallah, Binod Dhakal
Journal: Blood (2016)
Error in Coding of Questionnaire Scale in Studies of Children and Adolescents Following Parental Death
Authors: David A. Brent, Giovanna Porta
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Proteomic Characterization of the Multiple Myeloma Bone Marrow Extracellular Matrix
Authors: Siobhan Glavey, Alexandra Naba, Salomon Manier, Manuela Gambella, Alberto Rocci, Antonio Sacco, John M. Asara, Michele Moschetta, Michaela R. Reagan, Yuji Mishima, Yawara Kawano, Aldo M Roccaro, Antonio Palumbo, Richard O. Hynes, Irene M. Ghobrial
Journal: Blood (2014)
Polycomb-mediated repression of EphrinA5 promotes growth and invasion of glioblastoma
Authors: Thomas Oliver Millner, Barbara Ricci, Xinyu Zhang, Nicola Pomella, Silvia Marino
Journal: Neuro-Oncology (2019)

Abstract Introduction The epigenetic regulator Bmi1 is essential for the self-renewal of neural stem cells (NSC), and highly expressed in glioblastoma (GBM) stem/initiating cells (GIC), where knockdown significantly reduces tumour growth in xenograft models. We have used a combined genome-wide and target gene-driven approach to identify EphrinA5 (EfnA5) as a mediator of Bmi1 function in mouse and human GIC. Methods and results We compared mGIC, from a PTEN/p53 deletion mouse model, to matched NSC. Combined ChIPSeq and RNASeq showed a differential redistribution of the repressive PRC mark H3K27me3 in mGIC, and that transcriptional regulation is Bmi1-dependent in a proportion of H3K27me3 marked genes. Subsequently, using shRNA knockdown, we show that Bmi1 regulates cell morphology, proliferation and migration/invasion via repression of EfnA5 in mGIC, and that the same mechanism is essential for GBM development in an allograft model. To confirm the translational potential of the BMI1/EFNA5 pathway we examined published RNA microarray, RNAseq and single-cell RNAseq datasets and found a significant inverse relationship between BMI1 and EFNA5. Finally, we show that BMI1 also regulates cell proliferation via repression of EFNA5 in primary human GIC in vitro. Conclusions We present evidence from a mouse model, human expression datasets and human primary cells showing that the Bmi1-EfnA5 pathway plays a prominent regulatory role in GIC. As the anti-proliferative role of BMI1 silencing is mediated by de-repression of EFNA5 in hGIC, precision targeting of Ephrin signalling, for example with agents that mimic EFNA5 action, could be an effective therapeutic tool in human GBM overexpressing BMI1.
Alternative Payment for Radiation Oncology
Authors: David H. Howard, Mylin A. Torres
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial
Authors: Marcelo Cypel, Jordan J Feld, Marcos Galasso, Rafaela V Pinto Ribeiro, Nikki Marks, Magdalena Kuczynski, Deepali Kumar, Ilona Bahinskaya, Vanderlei S Bagnato, Cristina Kurachi, Arthur S Slutsky, Jonathan C Yeung, Laura Donahoe, Marc de Perrot, Kazuhiro Yasufuku, Andrew Pierre, Matthew Binnie, Cecilia Chaparro, Tereza Martinu, Manyin Chen, Jussi Tikkanen, Chung-Wai Chow, Aman Sidhu, Thomas K Waddell, Shaf Keshavjee, Lianne G Singer, Atul Humar
Journal: The Lancet Respiratory Medicine (2019)
Redo-Surgery for Recurrent Glioblastoma: A 10-year single-institution series
Authors: José Lavrador, Prajwal Ghimire, Shami Acharya, Angela Swampillai, Jennifer Glendenning, Lucy Brazil, Omar Alsahib, Richard Gullan, Francesco Vergani, Ranjeev Bhangoo, Keyoumars Ashkan
Journal: Neuro-Oncology (2019)

Abstract Introduction Multiple surgeries for recurrent / progressive glioblastomas is a matter of debate within the neuro-oncology community reflecting the higher risk of complications and the limited adjuvant treatment options for patients who recurred after initial treatment. Therefore it is crucial to identify who may benefit of a more aggressive approach and if the neurosurgical practice has changed in the last years. Methods Single-Neuro-Oncology Surgical Centre (1 neurosurgical and 2 medical neuro-oncology units) retrospective cohort study of patients with more than one surgery for intracranial Glioblastoma Multiforme (GBM). All patient diagnised with GBM at the time of the first surgery in the period between 2009–2018. Second surgery within 2-months time following initial biopsy or surgical complication or prior to chemo-radiotherapy were excluded. Demographic and clinical data was collected from the medical records. Results 96 patients underwent second surgery (63 males, 33 females, mean age of 52.6) met criteria for surgery at progression. At the time of the first surgery, the extent of resection (EOR) was: 15 biopsy, 17 subtotal rescetion (STR) and 35 gross total resection (GTR) – 29 missing data. With regards to the molecular markers, 26 were IDH mutant, 73 were MGMT methylated. All of the patients recieved adjuvant chemoradiotherapy following the STUPP protocol prior. Conclusion Our data corresponds to the data in the current literature. Further qualitative study will provide an insight into the effectiveness and aggressive approach to the recurrent GBMs.
Whole Exome Analysis of Myelodysplastic Syndromes Using Next-Generation Resequencing Technology
Authors: Kenichi Yoshida, Masashi Sanada, Yasunobu Nagata, Ryoichiro Kawahata, Motohiro Kato, Aiko Matsubara, Jyunko Takita, Hiraku Mori, Ken Ishiyama, Takayuki Ishikawa, Shuichi Miyawaki, Naoshi Obara, Shigeru Chiba, Seishi Ogawa
Journal: Blood (2010)